drugset / Trial / NCT05925504
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
Phase 2
Recruiting
36 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Beijing Health Alliance Charitable Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single center, single-arm, phase 2 study. The aim of this study is to evaluate the efficacy and safety of Luspatercept for Patients with Lower-risk Myelodysplastic Syndromes (MDS).
Timeline
- Start
- 2023-07-01
- Primary completion
- 2026-06-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Luspatercept | Protein / enzyme biologic | 1.75 mg/kg | Subcutaneous |